This article was originally published on 14 February 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
The science of intradermal delivery
Sanofi-Pasteur had been developing its Intanza/IDflu intradermal influenza vaccine using a novel microinjection system (Becton Dickinson's Soluvia® prefillable microinjection system) designed to deliver a reduced antigen dose into the dermis - a tissue rich in antigen-presenting cells - rather than the subcutaneous or intramuscular space. The theoretical basis was sound: by targeting antigen delivery to the skin's dense network of Langerhans cells and dendritic cells, an immune response could be generated with significantly less antigen than conventional intramuscular injection.
Antigen dose per strain in Sanofi's intradermal formulation, compared to 15µg per strain in standard intramuscular seasonal flu vaccines - representing a 40% dose reduction
Clinical advantages and limitations
Clinical data from 2007-2008 showed that the intradermal vaccine met non-inferiority criteria against standard intramuscular vaccination in the primary target adult population. In elderly subjects - traditionally the most commercially important segment for influenza vaccines - results were more mixed, with some studies suggesting that the immune response advantage of intradermal delivery was less pronounced in immunosenescent individuals. This was a commercially critical finding, as the elderly population accounted for the majority of influenza vaccine revenues in both Europe and the US.
"Intradermal delivery is scientifically elegant and addresses real clinical and logistical needs - but the flu vaccine market rewards volume and price competitiveness above innovation premium in most markets."